-
May 17, 2021
Antengene Announces the Completion of the Quantitative and Systems Pharmacology Modeling for ATG-101 in Preparation for First-in-Human Trial
-
May 14, 2021
Antengene Announces the IND Approval for Eltanexor in Patients with Advanced Solid Tumors in Mainland China
-
May 14, 2021
Antengene Announces the Completion of Its Manufacturing Center in Shaoxing to Accelerate the Commercialization of Novel Anti-Cancer Therapies
-
May 14, 2021
VOLUNTARY ANNOUNCEMENT-NMPA APPROVAL OF IND APPLICATION FOR A PHASE IB/II CLINICAL TRIAL OF ELTANEXOR IN ADVANCED SOLID TUMORS
-
May 12, 2021
VOLUNTARY ANNOUNCEMENT-NMPA APPROVAL OF IND APPLICATION FOR A PHASE III CLINICAL TRIAL OF SELINEXOR IN ADVANCED OR RECURRENT ENDOMETRIAL CANCER
-
May 12, 2021
Antengene Announces IND Approval in China for a Global Phase III Trial of Selinexor in Advanced or Recurrent Endometrial Cancer
